000132866 001__ 132866
000132866 005__ 20240229105036.0
000132866 0247_ $$2doi$$a10.3389/fonc.2018.00098
000132866 0247_ $$2pmid$$apmid:29670858
000132866 0247_ $$2pmc$$apmc:PMC5894008
000132866 0247_ $$2altmetric$$aaltmetric:35365939
000132866 037__ $$aDKFZ-2018-00509
000132866 041__ $$aeng
000132866 082__ $$a610
000132866 1001_ $$0P:(DE-He78)c11560e565b42737e809a8b3cedf3254$$aTsiouris, Angeliki$$b0$$eFirst author$$udkfz
000132866 245__ $$aHealth Care Professionals' Perception of Contraindications for Physical Activity During Cancer Treatment.
000132866 260__ $$aLausanne$$bFrontiers Media$$c2018
000132866 3367_ $$2DRIVER$$aarticle
000132866 3367_ $$2DataCite$$aOutput Types/Journal article
000132866 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525866300_15505
000132866 3367_ $$2BibTeX$$aARTICLE
000132866 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132866 3367_ $$00$$2EndNote$$aJournal Article
000132866 520__ $$aSuggested medical contraindications for physical activity (PA) during cancer therapy might have an influence on PA recommendation behavior of Health Care Professionals (HCP). The purpose of the present study was to examine perceptions of physicians and oncology nurses (ON) toward specific medical conditions as contraindications for PA during cancer treatment.A total of 539 physicians and 386 ON were enrolled in this cross-sectional survey. HCP judged 13 medical conditions as to whether they are contraindications for PA during cancer treatment. Answering format was 'no contraindication'/'potentially a contraindication'/'yes, a contraindication.'χ2 analyses revealed significant differences between general practitioners, specialized physicians, and ON in their perception of 10 medical conditions. Approximately half of the medical conditions were answered cautiously, showing high numbers on the response option potentially (36-72%). Moreover, physicians' ratings differed significantly depending on their practical experience with particular medical conditions. Those being familiar with a specific medical condition was more permissive to PA during treatment, with effect sizes (Cramer's V) ranging from 0.13 to 0.27.Results indicate high cautiousness among HCP in judging medical conditions and their impact on PA during cancer treatment. However, group comparisons show that familiarity and clinical experience with potential contraindications facilitate a confident handling of safety issues, which at best leads to higher levels of PA recommendations during cancer treatment.
000132866 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132866 588__ $$aDataset connected to CrossRef, PubMed,
000132866 7001_ $$aUngar, Nadine$$b1
000132866 7001_ $$0P:(DE-He78)6911b891e4f82e142d099f0aa249c37d$$aHaussmann, Alexander$$b2$$udkfz
000132866 7001_ $$aSieverding, Monika$$b3
000132866 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4$$udkfz
000132866 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b5$$eLast author$$udkfz
000132866 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2018.00098$$gVol. 8, p. 98$$p98$$tFrontiers in oncology$$v8$$x2234-943X$$y2018
000132866 909CO $$ooai:inrepo02.dkfz.de:132866$$pVDB
000132866 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c11560e565b42737e809a8b3cedf3254$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132866 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6911b891e4f82e142d099f0aa249c37d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132866 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132866 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132866 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132866 9141_ $$y2018
000132866 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132866 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132866 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132866 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132866 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132866 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000132866 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132866 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000132866 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132866 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000132866 980__ $$ajournal
000132866 980__ $$aVDB
000132866 980__ $$aI:(DE-He78)G210-20160331
000132866 980__ $$aUNRESTRICTED